Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy Beltran, Himisha , Wyatt, Alexander W , Chedgy, Edmund C ... - - Clin. Cancer Res. - 2017 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90203
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer Eastham, James A. , Heller, Glenn , Halabi, Susan ... - - J. Clin. Oncol - 2020 Manuscript - Primary - Primary - GU - CALGB-90203
Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC) Morris, Michael J. , Heller, Glenn , Bryce, Alan , Armstrong, Andrew ... - ASCO - J Clin Oncol - 2019 Abstract - Primary - Primary - GU - A031201
